financetom
Business
financetom
/
Business
/
Why MP Materials Stock Is Falling Thursday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why MP Materials Stock Is Falling Thursday?
Mar 19, 2026 9:45 AM

MP Materials Corp ( MP ) shares are trading lower during Thursday's session. The rare earth miner is facing a dual threat of macroeconomic instability and internal selling pressure.

Geopolitical Tensions Rock Markets

Global markets are reeling from escalating Middle East conflicts. Reports indicate an attack on Iran's South Pars gas field. Additionally, Qatar's Ras Laffan LNG facility sustained damage.

The Nasdaq has dropped 0.72% while the S&P 500 shed 0.58%. The S&P 500 Materials sector is sliding 2.4% in response.

C-Suite Offloads Shares

Company-specific pressure is mounting following small insider selling. According to Benzinga, CFO Ryan Corbett sold $2.76 million in stock on March 17. This sale reduced his total ownership by 26.28%.

General Counsel Elliot Hoops also shed his position through sales in January and March.

Short Interest Landscape

The latest short interest report shows a slight decline in bearish bets. Short interest fell from 24.79 million to 23.32 million shares. Currently, 14.41% of the company's float is sold short. Based on average volume, shorts would need 4.85 days to cover.

Technical Analysis

MP is trading 11.3% below its 20-day simple moving average (SMA) and 12.2% below its 100-day SMA, showing the stock is in a pullback phase versus its intermediate trend.

Even after the drop, shares are up 96.01% over the past 12 months, and the stock is positioned closer to its 52-week low than its 52-week high.

The RSI is at 45.71, which sits in neutral territory. Meanwhile, MACD is at -0.3727 and below its signal line at -0.2347.

Key Resistance: $61.50

Key Support: $51.00

MP Stock Price Activity: MP Materials ( MP ) shares were down 9.26% at $52.21 at the time of publication on Thursday, according to Benzinga Pro data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer
Sector Update: Consumer
Aug 8, 2025
03:22 PM EDT, 08/08/2025 (MT Newswires) -- Consumer stocks advanced late Friday afternoon with the Consumer Staples Select Sector SPDR Fund (XLP) increasing 0.3% and the Consumer Discretionary Select Sector SPDR Fund (XLY) rising 0.2%. In corporate news, Sweetgreen ( SG ) shares tumbled 26%, a day after the company posted a wider-than-expected loss and revenue miss in Q2 and...
Trump fires IRS commissioner, Bessent named acting head
Trump fires IRS commissioner, Bessent named acting head
Aug 8, 2025
(Reuters) -U.S. President Donald Trump is removing Billy Long as the commissioner of the Internal Revenue Service and Treasury Secretary Scott Bessent will temporarily serve as acting commissioner, a White House official and a source familiar with the matter said on Friday. The New York Times, which first reported the news, said Long, a former congressman from Missouri, was expected...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Gilead Sciences' HIV Drug Yeztugo Unlikely to Deliver Significant Contributions Until 2028, Oppenheimer Says
Gilead Sciences' HIV Drug Yeztugo Unlikely to Deliver Significant Contributions Until 2028, Oppenheimer Says
Aug 8, 2025
03:22 PM EDT, 08/08/2025 (MT Newswires) -- Gilead Sciences' ( GILD ) recently launched HIV prevention drug Yeztugo is unlikely to generate any significant financial impact until 2028, Oppenheimer said in a note emailed Friday. The brokerage said it sees revenue growth for the biopharmaceutical company of 5% to 6% by 2028, primarily driven by antibody-drug conjugate Trodelvy's 1L expansion...
Copyright 2023-2026 - www.financetom.com All Rights Reserved